louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03533309: Accuracy of Computer Guided Versus Conventional Ridge Splitting of Horizontal Deficient in Maxillary Anterior Alveolar Ridge
Official title: Accuracy of Computer Guided Versus Conventional Ridge Splitting of Horizontal Deficient in Maxillary Anterior Alveolar Ridge (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ridge Deficency
Keywords: horizontal defect, Anterior maxillary
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-05-23
Enrollment: 14
Sex: ALL
Minimum age (years): 16
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In patient with horizontal deficiency in alveolar ridge of the anterior maxilla, Dose computer Guided stent enhance the accuracy and clinical outcome vs conventional ridge splitting surgery????

Detailed description: PICO P- Horizontal deficient alveolar ridge in Anterior Maxillary Region I- Computer guided surgical cutting guide C- Conventional alveolar ridge splitting O- Clinical outcome and radiographic outcomes Primary outcome: Accuracy In computer Guided: CBCT will performed pre-operative and post-operative for measure the difference of degree in superimposition after ridge splitting.

In conventional method: Ridge mapping will applied in preoperative clinical evaluation, and measure in post-operative, the difference in splitting will calculate in millimeter (mm) Secondary outcome: Thickness of buccal cortical plate In both technique CBCT will performed and measuring the Both Buccal and palatal cortical bone in millimeter(mm)

Eligibility criteria: Inclusion Criteria:

* Partial edentulous in the aesthetic zone.
* Patient with bucco-lingual bone width is 3 mm or greater but \< 6mm
* Normal alveolar bone height
* Adequate oral hygiene
* Free of soft tissue or dental pathology
* Patients accepting to participate in the study

Exclusion Criteria:

* Patient medically compromised.
* Uncooperative patient.
* Poor oral hygiene and periodontal disease.
* Patients who smoked and pregnant women
* Systemic disease directly affecting bone healing
* Atrophic ridges (1.5 mm or less)
* History of radiotherapy \& treatment with bisphosphonates.

Primary outcomes:
measure: Accuracy
timeFrame: up to 4 months
Secondary outcomes:
measure: Thickness of buccal cortical plate
timeFrame: up to 4 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04635709: Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis
Official title: Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bladder Dysfunction on Patients With Multiple Sclerosis
Lead sponsor: Taibah University
Sponsor class: OTHER
First posted: 2020-11-19
Enrollment: 50
Sex: MALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: study the effect of behavioral therapy and interferential current on management of bladder dysfunction in patients with multiple sclerosis

Detailed description: Fifty patients with multiple sclerosis (MS) (secondary progressive type SPMS) suffering from bladder dysfunction were divided equally into two groups randomly; Group A received biofeedback training (behavioral therapy) while group B received interferential training. Both groups were assessed by urodynamics for detrusor pressure and maximum flow rate before and after eight weeks of behavioral therapy and interferential training.

Data analysis was managed using SPSS for windows, version 22 (SPSS, Inc., Chicago, IL). The current test involved two independent variables. The first one was the (tested group); between subject factors which had two levels (group A received behavioral therapy and group B who received IF ) .The second one was the (measuring periods); within subject factor which had two levels (pre, post). In addition, this test involved two tested dependent variables (detrusor pressure and maximum flow rate ) .T independent and dependent tests were used to compare between and within groups respectively. Data was considered statistically significant when P \< .05

Eligibility criteria: Inclusion Criteria:

* All the patients were referred by a neurologist and the diagnosis was confirmed by the Magnetic Resonance Image (MRI).The duration of being diagnosed as SPMS for both groups were between one to two years. All the selected patients had normal mental examination according to mini mental scale .Also, all the selected patients were medically stable.

Exclusion Criteria:

* Patients with any other neurological deficits or orthopedics abnormalities or with auditory dysfunction were excluded from this study. Patients with history of bladder dysfunctions before the diagnosis of MS or attaining any attack during the treatment period were also excluded.

Primary outcomes:
measure: Detruser pressure between and within groups
timeFrame: eight weeks
measure: Maximum flow rate between and within groups
timeFrame: eight weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Medina
country: Saudi Arabia
facility: Taibah University
Study officials:
affiliation: Taibah University ,saidi arab
name: walaa M Ragab, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06888609: Comparing Back Extensor and Core Stability Training in Kyphosis
Official title: Comparison of Back Extensor Strengthening Versus Core Stability Exercise in Patients With Thoracic Kyphosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Thoracic Kyphosis
Keywords: Posture
Spinal Alignment
Overall Functional Outcome
Pain
Range of Motion
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-03-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the effects of back extensor strengthening exercises versus core stability exercises on thoracic kyphosis in patients, assessing improvements in posture, spinal alignment, and overall functional outcomes

Detailed description: Kyphosis is the normal forward curvature of our spine and when this curvature becomes excessively increased is referred to as hyper kyphosis or Hunch back. Its normal value is between 20 and 40 degrees. When the thoracic kyphotic angle exceeds 40 degrees, it is referred to as hyper kyphosis. The three main types of kyphosis often seen in individuals are postural, Structural and congenital. Postural kyphosis is caused by high external load on individual spine having overall poor muscle strength. Sagittal misalignment can be caused by poor posture while sitting and standing as well as prolonged sitting.

Eligibility criteria: Inclusion Criteria:

* Adults aged 18-40 years with a diagnosis of mild to moderate thoracic kyphosis (Cobb angle between 40° and 60°).
* The presence of back pain or discomfort is attributed to kyphosis.
* Willingness to participate and commit to the study's duration (6 weeks of intervention and follow-up).
* Ability to provide informed consent.

Exclusion Criteria:

* Severe thoracic kyphosis (Cobb angle \> 60°).
* Other spinal conditions such as scoliosis or spinal fractures.
* Previous spinal surgery or contraindications to physical activity.
* Neurological disorders affecting motor function.
* Pregnancy or severe medical comorbidities that would preclude participation.

Primary outcomes:
measure: Change in Pain Intensity Measured by Visual Analogue Scale (VAS)
timeFrame: 12 Weeks
measure: Change in Thoracic Spine Range of Motion (ROM) Measured by Inclinometer
timeFrame: 12 Weeks
measure: Assessment of Postural Deformity Severity Using the Matthias Test
timeFrame: 12 Weeks
measure: Change in Disability Level Measured by Oswestry Disability Index (ODI)
timeFrame: 12 Weeks
measure: Change in Functional Disability Measured by Roland-Morris Disability Questionnaire (RDQ)
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Malakand
country: Pakistan
facility: DHQ Timergara & Batkhela
state: KPK
Study officials:
affiliation: Riphah International University
name: Ayesha Sadiq, MSPT (OMPT)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04483609: SF-QUALIVEEN Turkish Validity and Reliability Study
Official title: SF-QUALIVEEN Turkish Cultural Adaptation, Validity and Reliability Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Keywords: multiple sclerosis
urological dysfunction
assessment
scale
Lead sponsor: Istanbul Aydın University
Sponsor class: OTHER
First posted: 2020-07-23
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pre-test: 10 patients with multiple sclerosis will be evaluated.Inclusion and exlusion criteria listed above.

Validation and reliability: 70 patients with multiple sclerosis will be evaluated.Inclusion and exlusion criteria listed above.

Brief summary: Urological dysfunction is common in patients with Multiple Sclerosis (MS) and its prevalence has been reported at a high rate of 32-97%. Bladder dysfunction is associated with a significant deterioration in the quality of life of people with MS. In chronic diseases such as MS, patients experiences need to be measured directly in order to have information about patients perceptions about the effect of the disease on quality of life. However, there are a small number of valid and reliable Turkish scales on this subject.SF-Qualiveen is a validated scale for patients with MS who assess the urinary-specific quality of life by examining the impact of a wide range of bladder problems.The aim of our study is to make the Turkish cultural adaptation, validity and reliability of the SF-Qualiveen scale.

Detailed description: The aim of this study is to reveal the Turkish cultural adaptation, validity and reliability of the SF-Qualiveen scale. In our study, Sf-Qualiveen and Urogenital Distress Inventory (UDI-6) scales will be used. Pre-testing will be done in 10 patients with multiple sclerosis.Then, the validity and reliability of the scale will be performed in 80 patients with multiple sclerosis.

Eligibility criteria: Inclusion Criteria:

1. age 18-65;
2. definitive diagnosis of MS according to McDonald criteria;
3. ability to read and write in Turkish.

Exclusion Criteria:

1. acute attacks of MS (within 3 months);
2. cognitive impairment (Mini Mental test result 24 points and below);
3. any chronic disease other than MS;
4. active malignant tumors;
5. symptomatic urinary tract infections;
6. patients who changed treatment within the test-retest period.

Primary outcomes:
measure: SF-Qualiveen score
timeFrame: Baseline
Secondary outcomes:
measure: Urogenital Distress Inventory (UDI-6)
timeFrame: Baseline
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: İstanbul Üniversitesi-Cerrahpaşa
Study officials:
References:
Clinical trial NCT02272309: Neurophysiological Assessment of Healthy and Impaired Human Lower Urinary Tract Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lower Urinary Tract Symptoms
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2014-10-22
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Study part 1 will consist of sensory evoked cortical potential (SEP) measurements of the lower urinary tract (LUT) in healthy subjects using different stimulation frequencies from 0.25 to 3Hz to find the most effective frequency in regard to acquisition time for reliable SEP response rates. Study part 2 will consist of a series of consecutive SEP measurements in patients with LUT symptoms during low bladder volume and maximum cystometric capacity to assess reliability of measurements and influence of potential concomitant LUTS treatments.


Eligibility criteria: Inclusion Criteria:

healthy volunteers:

* Written informed consent,
* good mental and physical health,
* age \>18y,

Patients with LUTS and Patients with LUTS and treatment:

* Written informed consent,
* age \>18y,
* prior urodynamic investigation,
* LUTS since \>6months with or without detrusor overactivity

Exclusion Criteria:

healthy volunteers:

* any neurological or urological pathology,
* current pregnancy or lactation,
* urinary tract infection,
* hematuria,
* any previous pelvic or spine or craniocerebral surgery,
* any anatomical anomaly of the LUT or genitalia,
* any metabolic disease,
* any LUT malignancy,
* bladder capacity \<150mL,
* SDV at 60mL;

Patients with LUTS and Patients with LUTS and treatment:

* current pregnancy or lactation,
* urinary tract infection,
* gross hematuria

Primary outcomes:
measure: N1latency of LUT SEPs
timeFrame: 2-3 measurements within 4-16 weeks from first exam
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Universitätsklinik Balgrist
Study officials:
References:
citation: Liechti MD, van der Lely S, Knupfer SC, Abt D, Kiss B, Leitner L, Mordasini L, Tornic J, Wollner J, Mehnert U, Bachmann LM, Burkhard FC, Engeler DS, Pannek J, Kessler TM. Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction. NEJM Evid. 2022 Nov;1(11):EVIDoa2200071. doi: 10.1056/EVIDoa2200071. Epub 2022 Jul 7.
citation: van der Lely S, Stefanovic M, Schmidhalter MR, Pittavino M, Furrer R, Liechti MD, Schubert M, Kessler TM, Mehnert U. Protocol for a prospective, randomized study on neurophysiological assessment of lower urinary tract function in a healthy cohort. BMC Urol. 2016 Nov 25;16(1):69. doi: 10.1186/s12894-016-0188-9.
Clinical trial NCT02901509: Impact of the Chikungunya Outbreak in Reunion Island on the Quality of Life After 10 Years
Official title: Epidémie de Chikungunya à l'île de La Réunion : Effet à Dix Ans de l'Infection Sur la qualité de Vie Dans la Cohorte TELECHIK
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chikungunya Fever
Quality of Life
Keywords: Chikungunya
Quality of Life
Lead sponsor: Centre Hospitalier Universitaire de la Réunion
Sponsor class: OTHER
First posted: 2016-09-15
Enrollment: 386
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: TELECHIK cohort population drawn for telephone survey

Brief summary: QoLCHIK study aims at evaluating impact of chikungunya infection on the quality of life of infected people during the 2005-2006 outbreak in Reunion Island and followed in the TELECHIK cohort by comparing scores of SF-36 health survey.

Detailed description: QoLCHIK is a prospective cohort telephone study on the quality of life of people from the TELECHIK cohort, measured by the SF-36 health survey. TELECHIK was a telephone survey conducted 2 years after the 2005-2006 outbreak in Reunion Island and drawn from the SEROCHIK study which aimed at assessing the seroprevalence of chinkungunya over the island between august and october 2006.

A sample of 440 people (220 per group) was calculated and to be drawn from TELECHIK cohort, 220 with a serodiagnosis of chikungunya and 220 with negative serology.

Eligibility criteria: Inclusion Criteria:

* People from the TELECHIK cohort

Exclusion Criteria:

* People with other diseases or disorders which could impact quality of life (predefined list)
* Minor
* Elderly over 85 yo
* People with a risk of exposure (in an endemic/epidemic area) after 2005-2006 Reunion Island outbreak

Primary outcomes:
measure: Mean score SF-36 health survey
timeFrame: 1 year
Secondary outcomes:
measure: Mean score AQ-5D health survey
timeFrame: 1 year
Other outcomes:
Locations:
city: Saint Pierre
country: France
facility: Centre Universitaire de La Réunion
Study officials:
References:
Clinical trial NCT01452009: Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%
Official title: Three Month Safety and Efficacy Study of TRAVATAN® vs Travoprost Ophthalmic Solution, 0.004%
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Open Angle Glaucoma
Ocular Hypertension
Keywords: open angle glaucoma
ocular hypertension
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2011-10-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%


Eligibility criteria: Inclusion Criteria:

1. Patients 18 years of age or older
2. Either gender
3. Any race/ethnicity
4. Diagnosed with open-angle glaucoma (including patients with pseudoexfoliation and pigment dispersion) or ocular hypertension

Exclusion Criteria:

1. Patients with any form of glaucoma other than open-angle glaucoma.
2. Patients with a central cornea thickness greater than 620 μm
3. Patients with Shaffer angle Grade \< 2
4. Patients with a cup/disc ratio greater than 0.80
5. Patients with severe central visual field loss
6. Best-Corrected Visual Acuity score worse than 55 ETDRS letters (20/80 Snellen equivalent)
7. Chronic, recurrent or severe inflammatory eye disease
8. Clinically significant or progressive retinal disease
9. Other ocular pathology

Primary outcomes:
measure: Efficacy: mean IOP Efficacy as measured by mean IOP
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00835809: Multi Marker Approach Interest in Emergency in Acute Respiratory Insufficiency Diagnostic
Official title: Multi Marker Approach Interest in Emergency in Acute Respiratory Insufficiency Diagnostic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Respiratory Insufficiency
Keywords: Acute respiratory insufficiency respiratory
Biomarkers
Emergency
Intensive care unit
Prospective
Patient hospitalize in emergency or in intensive care unit
for acute respiratory insufficiency
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
Collaborators: name: Regional Clinical Research
First posted: 2009-02-04
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency and unit intensive care patient.

Brief summary: Biomarkers have an interest in clinic diagnostic ,therapeutic and prognosis in pathophysiologic situation including cardiovascular.But interest of biomarkers in diagnostic care of severe acute respiratory insufficiency remains to clear.

We propose to determine the more relevant marker combination in this case.

Detailed description: In urgence of a severe acute respiratory insufficiency,for thanks to an approach diagnostic, therapeutic and prognostic we propose to determine the more relevant biomarker combination.

An expert committee will compare the biomarker diagnostic and prognostic relevance thanks to all elements clinico-biological and patient monitoring.

Eligibility criteria: Inclusion Criteria:

* Oxygen saturation below or equal to 92% in ambient air.
* Respiratory frequence above 25 cycle per minute

Exclusion Criteria:

* Minors
* Pregnant or lactating women
* Patient without social security
* Patient hospitalize without consent
* Chest pain with acute coronary electro-cardiographic change leading immediate achievement of a diagnostic coronary angiography and/or therapeutic
* Pneumothorax

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Grenoble
country: France
facility: University Hospital Grenoble
Study officials:
affiliation: Emergency NGO Onlus
name: ARA SOMOHANO Claire, PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05814809: Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers
Official title: Phase I Study to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Onconic Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2023-04-18
Enrollment: 30
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and the pharmacokinetics of the JP-1366 20 mg tablet and capsule oral administration in healthy adult volunteers.


Eligibility criteria: Inclusion Criteria:

1. Subjects ≥ 19 years of age
2. Subjects who weigh ≥ 50 kg (or ≥ 45 kg in the case of females) with body mass index (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2

Exclusion Criteria:

1. Subjects with clinically significant diseases or a medical history related to the digestive system, cardiovascular system, endocrine system, respiratory system, blood and tumor, infections diseases, kidney and urinary system, psychiatric and nervous system, musculoskeletal system, immune system, otorhinolaryngology, skin, and ophthalmological system
2. Subjects who have a history of gastrointestinal surgery (except simple appendectomy or herniotomy) or have gastrointestinal disorders that may affect the absorption of the drug
3. Subjects who received inducers or inhibitors of drug metabolizing enzymes
4. Subjects who have hypersensitivity to this drug, ingredients of this drug, or benzimidazoles, or have a medical history thereof
5. Patients receiving drugs containing atazanavir, nelfinavir, or rilpivirine
6. Subjects who are judged ineligible to participate in this study by the principal investigator

Primary outcomes:
measure: AUCt of Zastaprazan(JP-1366 20mg)
timeFrame: Pre-dose(0 hour) and up to 34 hours in each period
measure: Cmax of Zastaprazan(JP-1366 20mg)
timeFrame: Pre-dose(0 hour) and up to 34 hours in each period
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yangji Hospital
Study officials:
References: